Hiv Associated Neurocognitive Disorders (Hand) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HIV-Associated Neurocognitive Disorders (HAND) encompass a spectrum of neurocognitive impairments caused by human immunodeficiency virus (HIV) infection of the central nervous system (CNS). Despite the success of combination antiretroviral therapy (cART) in suppressing systemic viral loads and extending life expectancy, HAND remains a major complication affecting an estimated 30–60% of people living with HIV (PLWH) worldwide . The brain serves as a viral sanctuary where HIV can persist and replicate even when peripheral viral suppression is achieved, leading to chronic neuroinflammation, synaptic injury, and progressive neurocognitive decline . [1]
HAND was first recognized in the 1980s as AIDS dementia complex (ADC), a devastating condition causing severe cognitive, motor, and behavioral dysfunction. With the advent of cART in the mid-1990s, the incidence of the most severe form (HIV-associated dementia) has declined dramatically, but milder forms of neurocognitive impairment have become more prevalent, representing an emerging challenge in chronic HIV management . [2]
The 2007 Frascati criteria established a standardized classification system for HAND, defining three categories of increasing severity : [3]
Overall estimated prevalence of any HAND category is approximately 44.9%, making it one of the most common neurological complications of HIV infection . [4]
HIV enters the CNS early during primary infection via a "Trojan horse" mechanism, crossing the blood-brain-barrier within infected monocytes and CD4+ T lymphocytes [5]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC4937456/). Once inside the CNS, the virus productively infects [microglia[/doi:10.1093/brain/awaa219">2[/doi:10.1093/brain/awaa219">2[/doi:10.1093/brain/awaa219">2/doi:10.1093/brain/awaa219">2<)(https://pmc.ncbi.nlm.nih.gov/articles/PMC10615506/). [^6]
HIV enters the CNS early during primary infection via a "Trojan horse" mechanism, crossing the blood-brain-barrier within infected monocytes and CD4+ T lymphocytes . Once inside the CNS, the virus productively infects microglia/. [^7]
HIV-1 Tat (transactivator of transcription): Secreted by infected cells, Tat directly impairs synaptic function, disrupts calcium homeostasis, promotes neuronal apoptosis, and potentiates excitotoxicity through nmda-receptor receptor] receptor dysregulation [5:1]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC4937456/)
gp120 (envelope glycoprotein): Triggers oxidative-stress and mitochondrial-dysfunction in neurons, and activates microglia:69-81. [doi:10.1038/nri1527" title="^6]: Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69-81. doi:10.1038/nri1527">6))
Vpr (viral protein R): Induces cell cycle arrest and apoptosis in neurons and glia [5:2]))](https://pmc.ncbi.nlm.nih.gov/articles/PMC4937456/)
Several HIV-encoded proteins exert direct neurotoxic effects: [^8]
HIV-1 Tat (transactivator of transcription): Secreted by infected cells, Tat directly impairs synaptic function, disrupts calcium homeostasis, promotes neuronal apoptosis, and potentiates excitotoxicity through nmda-receptor receptor] receptor] receptor dysregulation
gp120 (envelope glycoprotein): Triggers oxidative-stress and mitochondrial-dysfunction in neurons, and activates microglia/
Vpr (viral protein R): Induces cell cycle arrest and apoptosis in neurons and glia
HIV infection leads to increased permeability of the blood-brain-barrier through multiple mechanisms: viral proteins (Tat and gp120) directly disrupt tight junction proteins, inflammatory mediators degrade the basement membrane, and activated monocytes transmigrate across the endothelium. blood-brain-barrier breakdown allows entry of viral particles, infected cells, and neurotoxic plasma proteins into the brain parenchyma . [^11]
HAND involves vulnerability of neural circuits caused by synaptic degeneration and abnormal dendritic pruning. Loss of synaptic density, particularly in the hippocampus and cortex, correlates more closely with cognitive impairment than neuronal loss, paralleling mechanisms observed in alzheimers . [^12]
HAND typically affects the following cognitive domains: [^13]
Formal neuropsychological testing across multiple cognitive domains remains the gold standard for HAND diagnosis. A comprehensive battery should assess at least five cognitive areas, with demographically adjusted norms accounting for age, education, and cultural background . [^14]
cART remains the cornerstone of HAND management. Selection of ART regimens with high CNS penetration-effectiveness (CPE) scores may improve neurological outcomes, though this remains debated . Key considerations include: [^15]
memantine: nmda-receptor receptor] receptor antagonist to mitigate excitotoxicity
Minocycline: Anti-inflammatory and neuroprotective properties
Lithium: gsk3-beta inhibition and neuroprotection
Statins: Anti-inflammatory effects and blood-brain-barrier stabilization
Intranasal insulin: Targeting insulin signaling pathways in the brain
No FDA-approved medications specifically target HAND. Investigational approaches include : [^16]
memantine: nmda-receptor receptor] receptor] receptor antagonist to mitigate excitotoxicity
Minocycline: Anti-inflammatory and neuroprotective properties
Lithium: gsk3-beta inhibition and neuroprotection
Statins: Anti-inflammatory effects and blood-brain-barrier stabilization
Intranasal insulin: Targeting insulin signaling pathways in the brain
HAND shares several pathogenic mechanisms with classic neurodegenerative diseases, particularly alzheimers: [^17]
These overlapping mechanisms have led to the hypothesis that HIV infection may accelerate or predispose to Alzheimer's-type neurodegeneration . [^18]
The study of Hiv Associated Neurocognitive Disorders (Hand) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [^19]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [^20]
This section highlights recent publications relevant to this disease.
Gut microbiome remodeling induced by microplastic exposure in humans. ↩︎
Meta-analysis of handgrip strength in subjects with high-normal or mildly increased uric acid compared to low-normal levels reported as quartiles. ↩︎
Exploring the mechanism of polymorphonuclear neutrophils against sepsis based on immune model. ↩︎
Effect of changes in the arm physical parameters on the minimum torque-change trajectories of human reaching movements. ↩︎ ↩︎
Community-Led Total Sanitation implementation in Malawi: process evaluation of a sanitation and hygiene intervention. ↩︎ ↩︎ ↩︎